Target Price | JPY651.25 |
Price | JPY964.00 |
Deviation |
32.44%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Sumitomo Dainippon Pharma 2026 .
The average Sumitomo Dainippon Pharma target price is JPY651.25.
This is
32.44%
register free of charge
JPY1,100.00
14.11%
register free of charge
JPY410.00
57.47%
register free of charge
|
|
A rating was issued by 8 analysts: 1 Analysts recommend Sumitomo Dainippon Pharma to buy, 4 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sumitomo Dainippon Pharma stock has an average upside potential 2026 of
32.44%
register free of charge
|
Mar '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion JPY | 314.56 | 372.55 |
43.38% | 18.44% | |
EBITDA Margin | 11.54% | 15.35% |
22.16% | 33.05% | |
Net Margin | -100.13% | 6.02% |
646.55% | 106.01% |
8 Analysts have issued a sales forecast Sumitomo Dainippon Pharma 2025 . The average Sumitomo Dainippon Pharma sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Sumitomo Dainippon Pharma EBITDA forecast 2025. The average Sumitomo Dainippon Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Sumitomo Dainippon Pharma Analysts have issued a net profit forecast 2025. The average Sumitomo Dainippon Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Mar '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share JPY | -792.79 | 56.40 |
322.71% | 107.11% | |
P/E | 16.35 | |
EV/Sales | 1.76 |
4 Analysts have issued a Sumitomo Dainippon Pharma forecast for earnings per share. The average Sumitomo Dainippon Pharma EPS is
This results in the following potential growth metrics and future valuations:
Sumitomo Dainippon Pharma...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.